| 引用本文： |
-
李莉,沈爱群,陈姝彤,等.上皮性卵巢癌患者化疗前后血清uPA含量变化及其对预后的影响[J].同济大学学报（医学版）,2015,36(4):80-85. [点击复制]
- LI Li,SHEN Ai-qun,CHEN Shu-tong,et al.Variation and prognostic value of serum uPA before and after chemotherapy in patients with epithelial ovarian carcinoma[J].Journal of Tongji University(Medical Science),2015,36(4):80-85. [点击复制]
|
|
| 摘要: |
| 目的 探讨上皮性卵巢癌患者化疗前及化疗后血清中纤溶酶原激活剂(uPA)含量的变化与预后的相关性。方法 107例卵巢恶性肿瘤患者行手术初治后,采用酶联免疫吸附试验(ELISA)检测化疗前及化疗后血清中uPA的含量。102例相同年龄段的正常健康妇女作为对照。结果 卵巢癌患者化疗前及化疗后血清中uPA的含量均明显高于正常对照组,差异有统计学意义(P＜0.05)。卵巢癌患者化疗前血清中uPA的水平高于化疗后,两者的差异有统计学意义(P＜0.05)。单因素生存分析中,化疗前uPA水平、化疗后uPA水平、FIGO分期、残余瘤灶直径大小和有无淋巴结转移是影响卵巢癌患者无进展生存期(progression-free survival, PFS)和总生存期(overall survival, OS)的相关因素(P＜0.05)。Cox比例风险模型分析显示,化疗前uPA水平和有无淋巴结转移与预后明显相关(P＜0.05)。结论 卵巢癌患者化疗前后血清中uPA水平高于正常人群,且其水平高低与FIGO分期、淋巴结转移及残存瘤灶大小高度相关。化疗前血清中uPA含量可作为评价患者PFS和OS的独立预后因子。 |
| 关键词: 上皮性卵巢癌 纤溶酶原激活剂 血清 预后 |
| DOI：10.16118/j.1008-0392.2015.04.016 |
| 通信作者: |
| 投稿时间：2015-01-19 |
| 录用日期： |
| 基金项目:国家自然科学基金(81101967) |
|
| Variation and prognostic value of serum uPA before and after chemotherapy in patients with epithelial ovarian carcinoma |
| LI Li,SHEN Ai-qun,CHEN Shu-tong,CHEN Ke-wei,LI Huai-fang,OUYANG Yi-qin |
| (Dept. of Gynecology, Tongji Hospital, Tongji University, Shanghai 200065, China) |
| Abstract: |
| Objective To investigate variation and prognostic value of serum urokinase-type plasminigen activator (uPA) before and after chemotherapy in patients with epithelial ovarian carcinoma. MethodsOne hundred and seven patients with ovarian carcinoma receive chemotherapy after cytoreductive surgery. Serum uPA levels were measured by enzyme-linked immunosorbent assay (ELISA) before chemotherapy and after 6 cycles of chemotherapy. One hundred and two health subjects served as controls. Results Serum uPA levels of patients were significantly higher than that of healthy women before and after chemotherapy (both P＜0.05); while uPA levels in patients before chemotherapy was significantly higher than those after the chemotherapy. Kaplan-Meier analysis indicated the serum uPA level before and after chemotherapy, FIGO stage, residual tumor size and lymph node metastasis were all associated with progression-free survival (PFS) and overall survival (OS) of ovarian carcinoma patients. Multivariate Cox regression analysis revealed that the serum uPA level and lymph node metastasis were independent prognostic factors for both PFS and OS (all P＜0.05). Conclusion Patients with epithelial ovarian carcinoma have high serum uPA levels both before and after chemotherapy. Pre-chemotherapy uPA level might be used for prognosis of ovarian carcinoma patients. |
| Key words: ovarian carcinoma urokinase-type plasminogen activator serum prognosis |
